Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 2/20 | 0.32 |
| ▸ | HTR6 | P50406 | 2/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | HRH2 | P25021 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR1E | P28566 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17595789 | 0.86 | LMNA (0.43) | LMNACYP19A1ALDH1A1MAPTKMT2A | |
| SCHEMBL19295061 | 0.86 | ALDH1A1 (0.36) | LMNAALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL20259606 | 0.84 | HRH1 (0.32) | HRH1HTR6BCHEADRA2ADRD2 | |
| SCHEMBL20259682 | 0.82 | HRH1 (0.38) | LMNAHRH1HTR6ADRA2ADRD2 | |
| SCHEMBL30406055 | 0.76 | ALDH1A1 (0.42) | LMNAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL17596607 | 0.75 | GAA (0.37) | LMNAALDH1A1MAPTKMT2A | |
| SCHEMBL25422550 | 0.74 | RAB9A (0.36) | LMNAMAPT | |
| SCHEMBL19300387 | 0.71 | — | — | |
| SCHEMBL18292162 | 0.71 | MEN1 (0.42) | GRIN1GRIN2BALDH1A1KMT2A | |
| SCHEMBL19295058 | 0.71 | KCNJ1 (0.42) | ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49687-E1 | Thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-10-10 | — | — | US | disclosed |
| US-RE49687-E1 | Thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-10-10 | — | — | US | disclosed |
| US-10246464-B2 | Thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-04-02 | — | — | US | disclosed |
| US-10246464-B2 | Thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-04-02 | — | — | US | disclosed |
| WO-2018106818-A1 | METHODS OF PROMOTING BETA CELL PROLIFERATION | KURA ONCOLOGY, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| US-20170247391-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | WELLSPRING BIOSCIENCES LLC | 2017-08-31 | — | — | US | disclosed |
| US-20170247391-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | WELLSPRING BIOSCIENCES LLC | 2017-08-31 | — | — | US | disclosed |
| WO-2016040330-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246464-B2 | Thienopyrimidine and thienopyridine compounds and methods of use thereof | MLLT1, MEN1, TERF2IP | LMNA 2254/4885HRH1 1310/4885HTR6 2860/4885 |
| US-20170247391-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | MLLT1, MEN1, TERF2IP | LMNA 2254/4885HRH1 1310/4885HTR6 2860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.